



**Stanley Fahn, M.D.**  
**Scientific Director**  
**Parkinson's Disease Foundation**

Stanley Fahn, M.D., is the H. Houston Merritt Professor of Neurology and Director of the Center for Parkinson's Disease and Other Movement Disorders at Columbia University. He has served as the Scientific Director of the Parkinson's Disease Foundation since 1973. He currently is the immediate Past-President of the American Academy of Neurology (AAN). Dr. Fahn founded the Movement Disorder Society and served as Chairman of its Steering Committee. After its constitution was approved, he was elected its first president. The Movement Disorder Society, an international organization of professionals active in this subspecialty, has honored him by naming one of the two principal lectureships at its annual International Congresses after him. He was the founding co-editor of the journal *Movement Disorders*, and served in this capacity for the first 10 years of the journal's existence, until 1996.

Dr. Fahn was also the Associate Editor of *Neurology* for 10 years. He has twice served as Chairman of the Advisory Committee on Peripheral and Central Nervous System Drugs for the Food and Drug Administration. He is currently on an NIH Oversight Committee to review and give advice on clinical trials on neuroprotection for PD. Dr. Fahn and his scientific colleagues at Columbia University were awarded an ongoing Morris K. Udall Parkinson's Disease Research Center of Excellence by the National Institutes of Health in 1999.

Dr. Fahn organized and executed the development of the Unified Parkinson's Disease Rating Scale (UPDRS) and modified and popularized the use of the Schwab England ADL score for global severity of this disease. Both of these rating scales are used world wide, the former to determine the severity of PD, and the latter as a measure of quality of life. He has participated in many clinical trials of a variety of therapeutic agents for PD. Along with Dr. Ira Shoulson, Dr. Fahn was a co-founder of the Parkinson Study Group (PSG), a consortium of clinical investigators dedicated to conducting controlled clinical trials on the prevention and treatment of Parkinson's disease.

Dr. Fahn has received numerous honors and delivered many titled lectures at a variety of universities around the world. The American Academy of Neurology honored him with the Wartenberg Award for outstanding clinical research in 1986, the First Movement Disorder Prize for outstanding contributions in this field in 1997, and their A. B. Baker Award for outstanding educator in neurology in 1996. The American Neurological Association awarded him the First Soriano Lectureship for excellence in research; and the Blepharospasm Association enrolled him in their Hall Of Fame. NIH selected Dr. Fahn

to deliver the 2000 Neurodegeneration Lecture. He received the Srinivasan Award in Chennai, India, in February 2002. In October 2002 he was elected a member of the Institute of Medicine of the U.S. National Academies. He was also elected as Honorary Member of the Movement Disorder Society in November 2002, and of the American Academy of Neurology in October 2003. The Annemarie Opprecht Foundation selected Dr. Fahn to receive the prestigious Parkinson Award for 2005 for his paper on the ELLDOPA project, published in *The New England Journal of Medicine*'s December 2004 issue. He currently serves as Chair of the World Parkinson Congress Steering Committee.